Company

Paion AG

Headquarters: Aachen, Germany

Employees: 50

CEO: Dr. James Neil Phillips ChB, M.B.A., M.D., MB, MBA

Market Cap

€221,858

EUR as of Jan. 1, 2024

US$245,038

Market Cap History

Paion AG market capitalization over time

Evolution of Paion AG market cap in the past 5 years

Market capitalizations are calculated from the opening stock price at the beginning of each month.

Market Cap History of Paion AG

Detailed Description

Paion AG, a specialty pharmaceutical company, develops and commercializes drugs for out-patient and hospital-based sedation, anesthesia, and critical care services worldwide. The company's lead product is Remimazolam, an ultra-short-acting intravenous benzodiazepine sedative/anesthetic, which is in final stage of clinical development for use in procedural sedation, as well as in other indications, such as general anesthesia and intensive care unit sedation. It has partnerships and license agreements with Cosmo Pharmaceuticals, Yichang Humanwell, R-Pharm, TR-Pharm, Hana Pharm, Pharmascience, and Mundipharma. Paion AG was founded in 2000 and is based in Aachen, Germany.

Top 1-year algo backtest: +269.94%

$10,000 in May 2023 would now be $36,994 by following this algorithm daily at market close.

Boost your stocks returns with Disfold AI... Now!

Try Disfold AI for FREE

Stocks & Indices

Paion AG has the following listings and related stock indices.


Stock: FSX: PA8 wb_incandescent

Stock: XETR: PA8 wb_incandescent

Stock: OTC: PAIOF wb_incandescent

Details

Headquarters:

Martinstrasse 10-12

Aachen, 52062

Germany

Phone: 49 2414 4530

Fax: 49 2414 453100